Investors & Media

Lynn Seely, M.D., has served as a member of our Board of Directors since April 2016 and is the Chair of the Compensation Committee. Currently, Dr. Seely serves as President and Chief Executive Officer of Lyell Immunopharma, a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Previously, Dr. Seely was President, Chief Executive Officer and a member of the Board of Directors of Myovant Sciences, Inc. a biopharmaceutical company focused on developing and commercializing innovative therapies for women’s and men’s health. Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc, where she led development of XTANDI® (enzalutamide) from the first-in-human clinical trial through global approvals. Dr. Seely has held various finance positions at Anesiva, Inc. (formerly Corgentech Inc.), Cytyc Health Corporation and ProDuct Health. Dr. Seely began her career as Associate Director of Clinical Development at Chiron Corporation. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine, completed her residency and served as Chief Resident in internal medicine at Yale-New Haven Hospital, and completed a fellowship in endocrinology and metabolism at the University of California, San Diego.